Skip to content

Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection

Application of Folic Acid-Targeted Near-Infrared-II (NIR-II) Carbon Dots in Ex Vivo Histopathological Analysis of Hepatocellular Carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07295340
Enrollment
20
Registered
2025-12-19
Start date
2026-01-01
Completion date
2027-10-01
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cancer

Keywords

liver cancer

Brief summary

This prospective, single-center observational study evaluates the diagnostic accuracy of a novel Folate-targeted Near-Infrared II Carbon Dot (FA-CDots) probe for the ex vivo assessment of Hepatocellular Carcinoma (HCC). Following standard radical hepatectomy, resected liver specimens will be incubated with the FA-CDots probe and imaged using a NIR-II fluorescence system. The study aims to determine the feasibility and accuracy of this technology in identifying tumor margins and micro-lesions by comparing the fluorescence imaging results with standard histopathological examination.

Interventions

DIAGNOSTIC_TESTEx Vivo FA-CDots Staining

The resected liver specimens are incubated with Folate-targeted Near-Infrared II Carbon Dots (FA-CDots) and imaged using a NIR-II fluorescence imaging system to identify tumor margins and micro-lesions. The results are compared with standard histopathology.

Sponsors

West China Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Primary diagnosis of Hepatocellular Carcinoma (HCC) confirmed clinically or by preoperative biopsy. 2. Scheduled for radical hepatectomy. 3. Preoperative imaging (CT/MRI) suggests indistinct tumor boundaries, infiltrative growth, or proximity to major vessels (expected margin \< 1cm). 4. Liver function classified as Child-Pugh Grade A. 5. ASA Physical Status classification I-III. 6. Participant or legal guardian willing to sign informed consent for the use of ex vivo tissues.

Exclusion criteria

1. Concomitant other malignant tumors. 2. Severe dysfunction of heart, lung, kidney, or brain unable to tolerate surgery. 3. Recurrent HCC. 4. Preoperative evidence of extrahepatic metastasis or major vascular invasion. 5. Received preoperative anti-tumor therapy. 6. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic Performance of FA-CDots (Sensitivity, Specificity, and AUC)Immediate ex vivo analysis post-surgeryEvaluate the accuracy of FA-CDots in distinguishing HCC tissue from normal liver tissue. Metric: Area Under the Receiver Operating Characteristic Curve (AUC), Sensitivity, and Specificity. Calculation: Based on the Signal-to-Background Ratio (SBR) of the fluorescence images. A Positive result is defined as an SBR \> 2.0 (threshold to be optimized). Gold Standard: The diagnosis is verified by standard histopathological examination (H&E staining) of the corresponding tissue sites.

Countries

China

Contacts

Primary ContactJiwei Huang Professor
huangjiwei@wchscu.cn18980606725

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026